Long-term follow-up of AAVAnc80-antiVEGF gene therapy in vestibular schwannoma
Follows adults with vestibular schwannoma who earlier received AAVAnc80-antiVEGF gene therapy in the inner ear.
Key facts
- Who runs it
- Eli Lilly and Company
- Where
- Dallas, United StatesSee the site
- Trial code
- Registry title
- Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
- Status
- Enrolling by invitation
- People taking part
- 100 people, planned
- Started
- 2 Mar 2026
- Expected to end
- Apr 2040
- Type of study
- Observational
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with vestibular schwannoma who already received AAVAnc80-antiVEGF gene therapy into the inner ear (cochlea) in an earlier clinical trial. This study follows them over the long term.
- Age
- 18 Years and older
- Sex
- All
- Disease stage
- Vestibular schwannoma, a non-cancerous tumour on the nerve between the ear and the brain.
- Earlier treatment
- Must have received AAVAnc80-antiVEGF into the cochlea in an earlier interventional clinical trial.
Main reasons for not taking part
- Any condition that would stop the person from completing the follow-up exams
- Any condition that the study doctor thinks makes the person unfit for the study
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- -Individual with vestibular schwannoma who received an intracochlear administration of
- AAVAnc80-antiVEGF in an interventional clinical trial
- -Participant willingness to comply with all study requirements as evidenced by successful completion of the informed consent process
Who cannot take part
- -Any condition that would not allow the potential participant to complete follow-up examinations during the course of the study and/or, in the opinion of the Investigator, makes the potential participant unsuitable for the study
Where in United States
- University of Texas, SouthwesternDallas, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This multi-center, observational, post-intervention LTFU study will monitor for safety and efficacy of AAVAnc80- antiVEGF in individuals with vestibular schwannoma who have previously received an intracochlear administration of AAVAnc80-antiVEGF in an interventional clinical trial
The group in the trial
- Study Participants
Individuals with vestibular schwannoma who received an intracochlear administration of AAVAnc80-antiVEGF in an interventional clinical trial.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Evaluation of the Long Term Safety and Efficacy of AAVAnc80-antiVEGF Gene Therapy in Individuals With Vestibular Schwannoma
- Plain-language title
- Long-term follow-up of AAVAnc80-antiVEGF gene therapy in vestibular schwannomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 4 November 2026